Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Preserving Patient Access To Primary Care Act Of 2009 Endorsed By American College Of Physicians
The 128,000-member American College of Physicians (ACP) has endorsed the Preserving Patient Access to Primary Care Act of 2009 (H.R. 2350), introduced by Rep. Allyson Schwartz (D-PA). "Primary care is the best medicine for better health and lower costs," ACP noted, "and this is the best medicine for curing the growing crisis in primary care."

Promoting Safer Childbirth - A Sri Lankan Success Story: Royal College of Obstetricians and Gynaecologists
Despite recent internal conflict, Sri Lanka has emerged as a success story in promoting safer childbirth. The country"s significant decline in maternal deaths will be presented today at the Royal College of Obstetricians and Gynaecologists (RCOG) South Asia Day. The conference gathers together a group of international experts to discuss maternal and child health in South Asia.
News of the day
Tamed Virus Wipes Out Cancer Safely
Cancer Research UK scientists have tamed a virus so that it attacks and destroys cancer cells but does not harm healthy cells, according to a paper published in PLoS Pathogens*.
Oncology

MDRNA, Inc. Receives Full FDA Approval Of Generic Calcitonin-Salmon Nasal Spray For Osteoporosis

MDRNA, Inc. (NASDAQ: MRNA) announced that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE: PAR) has launched the product. Calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin® nasal spray, marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin® were approximately $112 million in 2008, according to IMS Health data. On March 31, 2009, MDRNA and Par entered into an agreement under which Par acquired the Company"s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray and the Company"s FDA-approved, cGMP manufacturing facility in Hauppauge, New York, for an upfront cash payment and profit sharing on commercial sales for five years. "We are pleased that generic calcitonin-salmon nasal spray has received full FDA approval and has been launched by Par," stated J. Michael French, President and CEO of MDRNA. "Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs. I thank the team at MDRNA and Par for their superb efforts to bring this product to market." For additional product information, please visit http://www.parpharm.com/products. MDRNA, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009